Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Components and Changes in Restructuring Accruals (Detail) - USD ($) $ in Millions		3 Months Ended
		Mar. 30, 2025	Mar. 31, 2024
Restructuring Reserve [Roll Forward]
Balance, beginning	[1]	$ 2,120
Provision	[2]	621	$ 10
Utilization and other	[3]	(342)
Balance, ending	[4]	2,399
Other Current Liabilities [Member]
Restructuring Reserve [Roll Forward]
Balance, beginning		1,700
Balance, ending		1,800
Other Noncurrent Liabilities [Member]
Restructuring Reserve [Roll Forward]
Balance, beginning		437
Balance, ending		562
Employee Termination Costs [Member]
Restructuring Reserve [Roll Forward]
Balance, beginning	[1]	2,046
Provision		384
Utilization and other	[3]	(249)
Balance, ending	[4]	2,181
Asset Impairment Charges [Member]
Restructuring Reserve [Roll Forward]
Balance, beginning	[1]	0
Provision		173
Utilization and other	[3]	(173)
Balance, ending	[4]	0
Exit Costs [Member]
Restructuring Reserve [Roll Forward]
Balance, beginning	[1]	74
Provision		64
Utilization and other	[3]	80
Balance, ending	[4]	$ 218

[1] Included in Other current liabilities ($1.7 billion) and Other noncurrent liabilities ($437 million).

[2] In 2025, primarily represents cost-reduction initiatives. In 2024, primarily represented Seagen acquisition-related costs, largely offset by credits for cost-reduction initiatives. Amounts associated with our Biopharma segment: charges of $617 million for the three months ended March 30, 2025 (including charges of $587 million for our Realigning our Cost Base Program and credits of $4 million for our Manufacturing Optimization Program) and credits of $37 million for the three months ended March 31, 2024 for our Realigning our Cost Base Program.

[3] Other activity includes adjustments for foreign currency translation that are not material to our condensed consolidated financial statements.

[4] Included in Other current liabilities ($1.8 billion) and Other noncurrent liabilities ($562 million).